Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Xiao‐Jing Zhang's publication output changed over time?
ScholarIQpublication output · 2015–2021
Output grew100% over the shown period — from 1 works in 2015 to 2 in 2021.
1
1
3
2
2
2
201520162017201920202021
What are the most-cited papers on Xiao‐Jing Zhang?
ScholarIQmost cited works
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19
Peng Zhang, Lihua Zhu, Jingjing Cai, Fang Lei, Juan‐Juan Qin, Jing Xie, Ye-Mao Liu, Yan-Ci Zhao, Xuewei Huang, Lijin Lin, Xia Meng, Mingming Chen, Xu Cheng, Xiao Zhang, Deliang Guo, Yuanyuan Peng, Yan‐Xiao Ji, Jing Chen, Zhi‐Gang She, Yibin Wang, Qingbo Xu, Renfu Tan, Haitao Wang, Jun Lin, Pengcheng Luo, Shouzhi Fu, Hongbin Cai, Ping Ye, Bing Xiao, Weiming Mao, Li Liu, Youqin Yan, Mingyu Liu, Manhua Chen, Xiao‐Jing Zhang, Xinghuan Wang, Rhian M. Touyz, Jiahong Xia, Binghong Zhang, Xiaodong Huang, Yufeng Yuan, Rohit Loomba, Peter P. Liu, Hongliang Li
S10652568. 20201,185 CitationsOPEN ACCESS
Epidemiological Features of NAFLD From 1999 to 2018 in China
Jianghua Zhou, Feng Zhou, Wenxin Wang, Xiao‐Jing Zhang, Yan‐Xiao Ji, Peng Zhang, Zhi‐Gang She, Lihua Zhu, Jingjing Cai, Hongliang Li
S156174673. 2020702 Citations
Neuronal injuries in cerebral infarction and ischemic stroke: From mechanisms to treatment (Review)
Yunfei Zhao, Xiao‐Jing Zhang, Xinye Chen, Yun Wei
S192722082. 2021614 CitationsOPEN ACCESS
Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta‐Analysis
Feng Zhou, Jianghua Zhou, Wenxin Wang, Xiao‐Jing Zhang, Yan‐Xiao Ji, Peng Zhang, Zhi‐Gang She, Lihua Zhu, Jingjing Cai, Hongliang Li
S156174673. 2019612 Citations
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
Yunpeng Yang, Song Qu, Jingao Li, Chaosu Hu, Mingjun Xu, Weidong Li, Ting Zhou, Liangfang Shen, Hui Wu, Jinyi Lang, G. Hu, Zhanxiong Luo, Zhichao Fu, Shenhong Qu, Weineng Feng, Xiaozhong Chen, Shaojun Lin, Weimin Zhang, Xiaojiang Li, Yan Sun, Zhixiong Lin, Qin Lin, Lei Feng, Jianting Long, Jinsheng Hong, Xiaoming Huang, Lingzhi Zeng, Peiguo Wang, Xiaohui He, Ben Zhang, Qing Yang, Xiao‐Jing Zhang, Jianjun Zou, Wenfeng Fang, Li Zhang
The Lancet Oncology. 2021461 Citations
Related on ScholarIQ
Guangzhou University of Chinese Medicine
Institution
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19
Paper
Epidemiological Features of NAFLD From 1999 to 2018 in China
Paper
Neuronal injuries in cerebral infarction and ischemic stroke: From mechanisms to treatment (Review)
Paper
Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta‐Analysis
Paper
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
Paper